Close Menu

drug delivery

The company said that a large portion of the offering's proceeds would be used to end criminal and civil investigations over its past billing practices.

The firm's lead product is a blood-based assay, called Alibrex, which uses PCR technology to monitor stage IV solid tumor cancer therapy.

Results from a randomized clinical trial known as GIFT suggest that genotype-guided warfarin dosing is linked to fewer adverse events than clinical dosing.

This article has been updated to clarify details regarding Traversa Therapeutics' bankruptcy proceedings.

Roughly one year after securing €5 million ($6.5 million) in venture capital funding, Spanish oligonucleotide drug developer nLife Therapeutics has set its sights on initiating non-human primate testing of its core intranasal delivery technology, which it hopes will spur licensin

Less than a year after Traversa Therapeutics declared bankruptcy, the company's founders are making another run at the RNAi drugs space in the form of startup Solstice Biologics, which announced this week that it has raised $18 million in a Series A round of financing.

By Doug Macron
The National Institutes of Health last month handed out nearly $1.3 million in grant funding to support four research projects focused on developing siRNA-delivery technologies.

Leonardo Biosystems said this week that it has received the second half of a $2.5 million grant from the Texas Emerging Technology Fund to help develop its multi-stage drug-delivery technology.
The first half of the grant was received in April 2010.

Access Pharmaceuticals this week announced that it has signed a deal under which its CobaCyte and CobOral siRNA delivery technologies will be evaluated by an undisclosed pharmaceutical company.

By Doug Macron
About a year and a half after its founding, siRNA delivery firm Qualiber has secured a $30,000 low-interest loan from the North Carolina Biotechnology Center to help it with non-scientific startup activities.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.